Smith & Nephew edges higher after recent guidance, shares on FTSE 100 health care radar

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 11:10.

Smith & Nephew (GB0009223206) sits in the FTSE 100 as a global medical device group with a clear long-term focus on orthopedics and wound care. The stock opens the weekend with investors reassessing guidance, consensus expectations and sector positioning among health care peers such as Stryker and Zimmer Biomet.

What recent guidance shows

Smith & Nephew most recently updated investors with first-quarter 2026 figures and a reiterated full-year outlook in May, confirming an expectation of moderate revenue growth and margin progression supported by efficiency measures. The company reported underlying revenue growth driven by orthopedics and advanced wound management, while sports medicine and ENT contributed to overall momentum per its investor materials. The Smith & Nephew investor relations site details the latest guidance and quarterly trends

The reiterated guidance set out for 2026 emphasizes a balanced improvement in profitability, reflecting ongoing restructuring programs and portfolio optimization across regions. Smith & Nephew continues to target organic growth above the broader medical device market in selected segments, notably in knee and hip implants as well as negative pressure wound therapy devices, according to its recent statements. Investors now track how these targets align with broader health care sector developments, including rotation into defensive names and selective valuation re-rating documented in specialist commentary on European health care stocks. MarketWatch provides ongoing coverage of Smith & Nephew’s valuation and performance

Analyst consensus and sector context

On the consensus side, analysts covering Smith & Nephew broadly expect mid-single-digit revenue growth over the coming years, with margin expansion driven by operational efficiencies and mix improvements. Data aggregators show a blend of Buy and Hold recommendations, reflecting cautious optimism on execution and a recognition of previous margin pressure episodes, according to analyst surveys. MarketScreener’s consensus page summarizes recent analyst targets and ratings

Smith & Nephew competes globally with peers such as Stryker, Zimmer Biomet and Johnson & Johnson’s orthopedics division, making its long-term performance sensitive to innovation cycles, regulatory approvals and hospital capital spending patterns. Specialist health care coverage highlights that European health care shares, including FTSE 100 constituents, have recently seen renewed interest from investors rotating into laggard defensive sectors, which provides a supportive backdrop for established medical device names. Financial Times sector analysis outlines recent rotation into European health care stocks

The product behind the stock

Smith & Nephew generates revenue through a diversified portfolio of medical devices, notably orthopedic reconstruction implants, sports medicine devices and advanced wound management systems. Flagship offerings include knee and hip replacement systems alongside the PICO single-use negative pressure wound therapy device, used in hospitals and outpatient settings worldwide.

Where the stock trades today

Smith & Nephew shares (GB0009223206) trade on the London Stock Exchange as part of the FTSE 100 index, with the latest available price data showing the stock quoted in pounds sterling on 2026-06-26, 16:30 at approximately 12.50 GBP.

This article is for informational purposes only and does not contain investment advice, personal recommendations or an offer to buy or sell securities. All data were obtained from sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research and, if necessary, consult a qualified advisor before making investment decisions.